| |
Sept. 25 - 26, 2024 | San Diego, CA Learn out of the box strategies for MSLs to engage with KOLs and HCPs post-pandemic, successful approaches to establishing medical communications plans ahead of a launch. Complimentry Passes Available! Learn More. .png)
|
|
Today’s Big NewsAug 9, 2024 |
|
Transform the Industry with Your Innovation! Submissions are now open for the Fierce Life Sciences Innovation Awards. Click to submit your entry and learn more about the categories and criteria. 
|
|
| By Nick Paul Taylor Merck & Co. is paying $700 million upfront to challenge Amgen in a blood cancer market. The deal will give Merck global rights to Curon Biopharmaceutical’s CD3xCD19 bispecific, positioning the Big Pharma as a rival to Amgen and AstraZeneca in oncology and Cullinan Therapeutics in autoimmune disease. |
|
|
|
By Nick Paul Taylor AN2 Therapeutics is rethinking its business in response to lackluster midphase data, vowing to lay off half its employees and stop a phase 3 study as part of a pivot to early-stage projects. |
By Annalee Armstrong CEO David Ricks can see the companies setting up tents at basecamp behind Eli Lilly in an attempt to get a foothold of the obesity market. But Lilly's already been to the summit and is coming back down for another trip. |
By Kevin Dunleavy With Gilead on the verge of an FDA decision for its liver disease drug seladelpar, the company has paid Johnson & Johnson $320 million to exit an 18-year-old licensing agreement on the compound. The buyout removes Gilead’s obligation to pay an 8% royalty on sales of seladelpar. |
|
Maximize Your Brand Exposure From brand awareness to lead generation, our tailored marketing solutions help you achieve your objectives. Get noticed, start conversations, and drive demand with Fierce Biotech. Learn more now. 
|
|
By Darren Incorvaia,Zoey Becker,Gabrielle Masson Former Biogen Chief Medical Officer Maha Radhakrishnan, M.D., is now an executive partner at healthcare investment firm Sofinnova Investments. |
By Ayla Ellison,Gabrielle Masson,Annalee Armstrong In this week's episode of "The Top Line," we’re diving into Fierce Biotech’s annual Fierce 15 special report. |
By Darren Incorvaia French preclinical CRO NovAliX has found a new partner across the pond. Massachusetts-based manufacturer Bruker Corporation has announced a minority investment of an undisclosed amount in the drug discoverer. |
By Angus Liu Legend Biotech CEO Ying Huang, Ph.D., already had a lot on his plate when speculations of a potential geopolitical crackdown and the option of a buyout emerged. |
By Angus Liu Three large pharma companies are locked in a high-stakes antibody-drug conjugate race. Merck and Daiichi Sankyo teamed up on a DLL3 T-cell engager. Eisai inked a molecular glue degrader deal with BeyondSpring that could be worth up to $1.5 billion. And more. |
By Anastassia Gliadkovskaya The survey found that about a third of the workforce—or 60 million Americans—experience personal or family issues related to substance or alcohol use. This causes losses in productivity and increases in healthcare costs. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," we’re diving into Fierce Biotech’s annual Fierce 15 special report. |
|
|---|
|
|
|
Thursday, September 5, 2024 | 12pm ET / 9am PT Liquid biopsy is emerging as a revolutionary technology, offering swift and precise diagnostics. However, it still faces key challenges. Join us to learn more about the collaborative efforts of SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center, and AstraZeneca that are aimed at addressing disparities in cancer care. Register now. 
|
|
Whitepaper This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
Whitepaper Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
